苏黄止咳胶囊联合孟鲁司特治疗稳定期慢性阻塞性肺疾病的效果

Abstract
Figure/Table
References (27)
Related Citation (15)

Download: PDF (599 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the effect of Suhuang Zhike Capsules combined with Montelukast in the treatment of patients with stable chronic obstructive pulmonary disease (COPD). Methods From June 2017 to January 2019, 146 patients with stable COPD treated in Puren Hospital Affiliated to Wuhan University of Science and Technology were recorded as observation objects. The patients were divided into observation group and control group according to random number table method, with 73 cases in each group. The two groups were treated with routine treatment, on basis of which, the patients in the control group were treated with Montelukast, and the observation group was treated with Suhuang Zhike Capsules on basis of the control group. The two groups were treated for 3 months, and the efficacy, St george′s respiratory questionnaire (SGRQ) scores, pulmonary function, inflammatory factors and adverse reactions of the drugs were compared between the two groups. Results The total effective rate of the observation group was significantly higher than that of the control group (P ＜ 0.05). After treatment, the SGRQ scores in the two groups were significantly lower than those before treatment, and the observation group was significantly lower than that of the control group (P ＜ 0.05). After treatment, the forced expiratory volume in the first second (FEV1), FEV1/maximal vital capacity (FEV1/FVC), maximal ventilation volume (MVV) and residual volume/total lung volume (RV/TLC) in the two groups were significantly higher than those before treatment, which of the observation group were significantly higher than the control group (P ＜ 0.05). After treatment, C-reactive protein (CRP), interleukin (IL）-17, IL-8 and tumor necrosis factor-α (TNF-α) in the two groups were significantly lower than those before treatment, which of the observation group were significantly lower than the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). Conclusion Suhuang Zhike Capsules combined with Montelukast is effective in the treatment of stable COPD patients, and can improve the pulmonary function and inflammatory factor level of the patients, and the safety is also good, which is worth promoting.

Key words： Suhuang Zhike Capsules Montelukast Stable chronic obstructive pulmonary disease Efficacy Pulmonary function Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Dezhong DU Wenfeng WU Yuanming

Cite this article:

CHENG Dezhong DU Wenfeng WU Yuanming. Effect of Suhuang Zhike Capsules combined with Montelukast in the treatment of patients with stable chronic obstructive pulmonary disease[J]. 中国医药导报, 2020, 17(4): 163-166,170.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I4/163

[1] 吴蔚，王彬，汪伟，等.清金化浊方对慢性阻塞性肺疾病急性加重期痰热蕴肺证患者呼出气一氧化氮的影响[J].国际中医中药杂志，2018，40（11）：1025-1028.
[2] 马理华，段建明，吴洪亮.益肺胶囊联合茚达特罗治疗慢性阻塞性肺疾病稳定期的临床研究[J].现代药物与临床，2019，34（7）：2036-2041.
[3] 李璟，王丹.苏黄止咳胶囊辅助治疗慢性阻塞性肺疾病急性加重期患者的临床疗效观察[J].药品评价，2018，15（18）：60-61.
[4] 欧聪灵，张伟鹏，黎东芳，等.苏黄止咳胶囊治疗慢性阻塞性肺疾病急性加重期患者的临床疗效研究[J].中医临床研究，2018，10（12）：14-16.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南（2013年修订版）[J].中国医学前沿杂志：电子版，2013，6（2）：67-80.
[6] 徐鸥，郝青林，李锐洁，等.圣乔治呼吸问卷对慢性阻塞性肺疾病患者生活质量差异的调查[J].昆明医学院学报，2008，29（3）：71-75.
[7] Koblizek V. The position of tiotropium in new treatment guidelines for chronic obstructive pulmonary disease [J]. Vnitr Lek，2013，59（12）：1073-1080.
[8] 林文波.中医辨证治疗慢性阻塞性肺疾病临床疗效观察及其安全性评价[J].中国中医基础医学杂志，2016，22（2）：219-220.
[9] 高燕鲁，俞晓滢，满鑫，等.稳定期慢性阻塞性肺疾病药物治疗进展[J].山东医药，2016，56（41）：110-113.
[10] Hogg JC，Chu F，Utokaparch S，et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease [J]. N Engl J Med，2004，350（26）：2645-2653.
[11] 陈焕珍，戢秋明，李兰，等.孟鲁司特对中重度稳定期慢性阻塞性肺疾病的临床疗效及白三烯E4的作用研究[J].现代中西医结合杂志，2016，25（24）：2675-2678.
[12] 杨晓晴，陈广，陈小云，等.沙丁胺醇雾化吸入联合苏黄止咳胶囊治疗慢性阻塞性肺疾病急性加重期的效果[J].中国当代医药，2019，26（5）：47-49.
[14] 肖文香，程知音.噻托溴铵对慢性阻塞性肺疾病急性发作期患者血清炎性因子和血气分析指标的影响[J].中国医院用药评价与分析，2018，18（9）：1235-1237.
[15] 吴建顺，池燕，曹得胜，等.温阳活血汤对稳定期慢性阻塞性肺疾病脾肾阳虚证患者炎性反应因子的影响[J].世界中医药，2018，13（10）：2453-2455，2459.
[16] 马丽华.自拟扶正消阻方对稳定期慢性阻塞性肺疾病的改善作用观察[J].中国中医药科技，2019，26（5）：715-717.
[17] 李冰冰，李维，许涵，等.苏黄止咳胶囊联合复方甲氧那明治疗慢性阻塞性肺疾病稳定期的临床研究[J].现代药物与临床，2019，34（3）：734-737.
[18] 吴成周.孟鲁司特钠治疗稳定期慢性阻塞性肺疾病疗效评价[J].中国药业，2017，26（2）：47-49.
[19] 赵年昆，李岩.苏黄止咳胶囊治疗慢性阻塞性肺疾病急性发作期的临床疗效及长期随访观察[J].辽宁中医杂志，2017，44（6）：1235-1236.
[20] 贺建峰，姚旭升，杨静，等.基于关联规则算法的慢性阻塞性肺疾病及其协同发病分析[J].北京生物医学工程，2018，37（6）：618-623，630.
[21] 刘小伟，高亭，陈剑辉，等.苏黄止咳胶囊联合噻托溴铵对稳定期慢性阻塞性肺疾病肺功能及炎性因子影响[J].现代中医药，2018，38（6）：22-24.
[22] 邹艳丽，徐辉，周辉，等.苏黄止咳胶囊辅助治疗老年慢性阻塞性肺疾病急性加重期的临床观察[J].中医药导报，2017，23（19）：89-92.
[23] 郑新远，曲文一.孟鲁司特钠联合沙美特罗替卡松治疗慢性阻塞性肺疾病的疗效观察[J].中国医院用药评价与分析，2018，18（2）：202-204.
[24] 郭晓燕，腾飞，张惠勇，等.川芎平喘合剂治疗慢性阻塞性肺疾病的随机对照研究[J].西部中医药，2018，31（1）：1-4.
[25] 王晓平，王小虎，万毅新，等.苏黄止咳胶囊辅助治疗慢性阻塞性肺疾病急性加重期患者的临床评价[J].中国医院药学杂志，2016，36（11）：937-938.
[26] 折哲，石克华.复方佛耳草合剂对慢性阻塞性肺疾病急性加重患者气道炎症的影响[J].西部中医药，2018，31（9）：5-8.
[27] Gueli N，Verrusio W，Linguanti A，et al. Montelukast therapy and psychological distress in chronic obstructive pulmonary disease（COPD）：a preliminary report [J]. Arch Gerontol Geriatr，2011，52（1）：36-39.